SecBot SecBot
PRESS-RELEASE ·Filed Mar 2, 2026

SION

Sionna Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor mid-2026 topline data from ongoing trials as the next major catalyst; current financials reflect investment phase with no near-term profitability, but cash runway supports development without immediate dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$33.92
T+0 close · Mar 2, 2026 · via day close
Latest settled
+26.42%
T+60 · $42.88
Vs SPY
+17.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 2 $33.92entry
  2. T+1 · 9mo ago +0.50%α +1.42% · $34.09
  3. T+5 · 8mo ago +10.64%α +11.85% · $37.53
  4. T+20 · 8mo ago +8.08%α +16.02% · $36.66
  5. T+60 · 6mo ago +26.42%α +17.09% · $42.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sionna Therapeutics reported financial results for Q4 and full year 2025, highlighting increased R&D and G&A spending, a growing net loss, and a strong cash position of $310.3 million that funds operations into 2028. The company advanced its NBD1 stabilizer pipeline with Phase 1/2a trials on track for mid-2026 readouts, but no revenue-generating products or positive clinical outcomes were reported.

Key Financial Metrics

EPS
$-1.88

Key Facts

  • No revenue generated; biopharma company in clinical stage with no commercial products
  • Net loss increased to $75.3 million in 2025 from $61.7 million in 2024
  • Cash and equivalents totaled $310.3 million as of December 31, 2025, up from $168.0 million in 2024
  • SION-719 and SION-451 Phase 1 trials completed with topline data expected mid-2026
  • R&D expenses rose to $60.3 million in 2025 from $57.3 million in 2024
  • G&A expenses nearly doubled to $28.7 million in 2025 from $13.3 million in 2024

Financial Impact

Increased operating losses and higher G&A due to growth initiatives; cash runway extended to 2028

net losscash positionoperating expenses

Risk Factors

  • Clinical trial failure risk for SION-719 and SION-451 in mid-2026 readouts
  • Increasing net losses and lack of revenue may pressure valuation if trials underperform
  • Heavy reliance on successful development of unproven NBD1 stabilizer mechanism

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3247220

Track record

22 reports on SION

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +89.29% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 10, 20266d ago Press Release Neutral 5/10 Entry $3.70 Now $3.12 −15.68% settles Nov 17
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $3.57 to $3.12 Now $3.12 −12.61% ▼ −12.61% −10.91% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $3.65 to $3.70 Now $3.12 −14.52% ▲ +1.37% +1.96% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $6.02 to $5.15 Now $3.12 −48.17% ▼ −14.45% −13.26% vs SPY
  5. Sep 21, 20268w ago SC 13D/A Bearish 7/10 Entry $6.02 to $5.15 Now $3.12 +48.17% ▲ +14.45% +13.26% vs SPY
  6. Sep 17, 20268w ago 144 Bearish 5/10 Entry $5.96 to $5.23 Now $3.12 +47.65% ▲ +12.25% +13.52% vs SPY
  7. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $4.50 to $5.91 Now $3.12 +30.67% ▼ −31.33% −31.38% vs SPY
  8. Aug 6, 202614w ago 8-K Neutral 4/10 Entry $49.61 to $6.54 Now $3.12 −93.71% ▼ −86.82% −88.03% vs SPY
  9. Jul 9, 202618w ago Insider Cluster Neutral 4/10 Entry $45.29 to $45.29 Now $3.12 −93.11% · 0.00% +0.56% vs SPY
  10. Jul 9, 202618w ago Insider Cluster Bearish 5/10 Entry $45.29 to $45.29 Now $3.12 +93.11% · 0.00% −0.56% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (10h 16m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 2, 2026